GOSSAMER BIO INC
GOSSNASDAQTrading Snapshot
- Day Range
- $11.54 β $11.78
- 52-Week Range
- $9.10 β $309.60
- Volume
- $1.64B
- Avg Volume
- $1.88B
- Shares Outstanding
- 6.1M
- Next Earnings
- Nov 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $48M
- Last Q Revenue
- $9M
- P/E Ratio
- -0.3
- P/S Ratio
- 1.3x
- EPS (TTM)
- $-45.38
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.0%
Why Investors Own GOSS
- βHigh-growth profile β revenue up +36.2% YoY with expanding US Equity exposure.
- βHealthy economics β 63% gross margin and 8% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
GOSSAMER BIO INC
GOSS
StockOtter Β· stockotter.spaceAbout GOSSAMER BIO INC
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
Corient Private Wealth LP Purchases 1,647,315 Shares of Gossamer Bio, Inc. $GOSS
Corient Private Wealth LP increased its position in shares of Gossamer Bio, Inc. (NASDAQ: GOSS) by 41.3% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the βCompanyβ or βGossamerβ), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the tr
Hsbc Holdings PLC Increases Stock Position in Gossamer Bio, Inc. $GOSS
Hsbc Holdings PLC boosted its holdings in Gossamer Bio, Inc. (NASDAQ: GOSS) by 1,289.4% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Gossamer Bio, Inc. (Nasdaq: GOSS) (the Γ’ΒΒCompanyΓ’ΒΒ or Γ’ΒΒGossamerΓ’ΒΒ), a clinical-stage biopharmaceutical company focused on the development and commercializa
Gossamer Bio Announces 1-for-80 Reverse Stock Split
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the βCompanyβ or βGossamerβ), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the tr